	For the Year Ended December 31, 2015
		Rennova Health, Inc. Historical			CollabRx, Inc. (a)			Pro-Forma Adjustments			Combined

Net Revenues	$	18,393,038		$	425,000		$	–		$	18,818,038

Operating Expenses		62,626,045			4,881,000			–			67,507,045

Income (Loss) from operations		(44,233,007	)		(4,456,000	)		–			(48,689,007	)

Other income (expense)		474,215			(43,000	)		–			431,215

Income (Loss) before income taxes		(43,758,792	)		(4,499,000	)		–			(48,257,792	)

Provision for income taxes		(9,028,253	)		(269,000	)		–	(b)		(9,297,253	)

Net income (loss) attributable to Rennova Health		(34,730,539	)		(4,230,000	)		–			(38,960,539	)

Preferred stock dividends		1,627,188			–			(1,627,188	)(c)		–

Net income (loss) attributable to Rennova Health common shareholders	$	(36,357,727	)	$	(4,230,000	)	$	1,627,188		$	(38,960,539	)

Net income (loss) per common share:
Basic	$	(2.93	)							$	(2.93	)
Diluted	$	(2.93	)							$	(2.93	)

Weighted average number of common shares outstanding during the period:
Basic		12,423,294									13,299,637
Diluted		12,423,294									13,299,637


	For the Year Ended December 31, 2014
		Rennova Health, Inc. Historical			Epinex Diagnostics Laboratories, Inc.			Clinlab, Inc.		CollabRx, Inc.			Pro-Forma Adjustments			Combined

Net Revenues	$	57,927,820		$	44,299		$	98,446	$	498,000		$	–		$	58,568,565

Operating Expenses		42,272,826			329,258			94,414		5,936,000			–			48,632,498

Income (Loss) from operations		15,654,994			(284,959	)		4,032		(5,438,000	)		–			9,936,067

Other income (expense)		(273,362	)		12,753			1		(27,000	)		–			(287,608	)

Income (Loss) before income taxes		15,381,632			(272,206	)		4,033		(5,465,000	)		–			9,648,459

Provision for income taxes		7,561,300			–			–		(301,000	)		(2,532,555	)(b)		4,727,745

Net income (loss) attributable to Rennova Health		7,820,332			(272,206	)		4,033		(5,164,000	)		–			4,920,714

Preferred stock dividends		5,010,300			–			–		–			(5,010,300	)(c)		–

Net income (loss) attributable to Rennova Health common shareholders	$	2,810,032		$	(272,206	)	$	4,033	$	(5,164,000	)	$	5,010,300		$	4,920,714

Net income (loss) per common share:
Basic	$	0.23													$	0.37
Diluted	$	0.22													$	0.36

Weighted average number of common shares outstanding during the period:
Basic		12,247,978														13,296,716
Diluted		12,667,858														13,716,596

_______________

(a)

Reflects 2015 and 2014 results of operations prior to the acquisition dates. Clinlab was acquired on March 18, 2014, Epinex was acquired on August 26, 2014 and CollabRx was acquired on November 2, 2015. For the year ended December 31, 2014, CollabRx is included using its fiscal year ended March 31, 2015 financial statements.

(b)

Reflects changes in taxes, if any, resulting from including the aggregate net losses of acquired operations in the corporate tax return.

(c)

Reflects elimination of preferred stock dividend accruals resulting from the reverse merger with CollabRx.

Consideration allocation for acquisitions

Cash	$	4,737,773
Accounts receivable		54,675
Other current assets		105,700
Property and equipment		92,636
Accounts payable and accrued expenses		(1,120,000	)
Deferred revenue		(123,000	)
Other liabilities		(520,070	)
Derivative liabilities		(1,578,976	)
Identifiable intangible assets		170,000
Total identifiable net assets		1,818,738

Goodwill		10,470,559

Total consideration	$	12,289,297

Consideration allocation for acquisitions

Consideration Given:

Cash at closing	$	100,000
Acquisition Notes		385,545
Series E Convertible Preferred Stock (100,000 shares)		800,000
Contingent consideration adjustment		(43,800	)

	$	1,241,745
Fair value of identifiable assets acquired and liabilities assumed:

Cash	$	36,677
Property and equipment, net		26,983
Deposits		285
Accounts payable		(227,855	)
Accrued expenses		(75,945	)
Identifiable intangible assets		900,000
Total identifiable net assets		660,145

Goodwill		581,600

Total consideration	$	1,241,745

Consideration allocation for acquisitions

Consideration Given:

Cash at closing	$	500,000
Common stock (10,000 shares)		25,000
Contingent acquisition liability		150,000

Total Consideration	$	675,000

Fair value of identifiable assets acquired and liabilities assumed:

Accounts receivable	$	93,270
Property and equipment, net		7,005
Software		182,000
Accounts payable		(95,086	)
Identifiable intangible assets		213,000
Total identifiable net assets		400,189

Goodwill		274,811

Total consideration	$	675,000

Consideration allocation for acquisitions

Consideration Given:

Cash at closing	$	1,000,000
Series D Convertible Preferred Stock (200,000 shares)		1,250,000
Contingent acquisition liability		54,017

Total Consideration	$	2,304,017

Fair value of identifiable assets acquired and liabilities assumed:

Cash	$	31,671
Accounts receivable		54,017
Other current assets		241
Software		1,252,000
Deposits		700
Accounts payable		(4,942	)
Accrued expenses		(39,202	)
Identifiable intangible assets		152,000
Total identifiable net assets		1,446,485

Goodwill		857,532

Total consideration	$	2,304,017